The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Advancements in menin inhibitors for acute leukemias: insights from EHA 2024
Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, discusses promising new targeted therapies for acute leukemias, specifically menin inhibitors, which show potential in inhibiting growth and inducing differentiation in leukemias with KMT2A rearrangements and NPM1 mutations. Dr Wang comments on the potency and reduced resistance of these inhibitors, as well as the potential efficacy of triplet therapy involving these agents. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
